83
Views
12
CrossRef citations to date
0
Altmetric
Diagnostic Profile

Implications of EGFR PharmDx™ Kit for cetuximab eligibility

&
Pages 141-148 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (11)

Hang-Ping Yao, Rachel Hudson & Ming-Hai Wang. (2020) RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1873:2, pages 188360.
Crossref
Aaron R. Ellison & David A. Stanforth. 2019. Companion and Complementary Diagnostics. Companion and Complementary Diagnostics 243 263 .
Sreedhar Reddy Suthe, Hang-Ping Yao, Tian-Hao Weng, Chen-Yu Hu, Liang Feng, Zhi-Gang Wu & Ming-Hai Wang. (2018) RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE. Molecular Cancer Therapeutics 17:12, pages 2654-2664.
Crossref
João Renato Rebello Pinho, Roberta Sitnik & Cristóvão Luis Pitangueira Mangueira. (2014) Personalized medicine and the clinical laboratory. Einstein (São Paulo) 12:3, pages 366-373.
Crossref
Emmy D.G. Fleuren, Yvonne M.H. Versleijen-Jonkers, Sandra Heskamp, Carla M.L. van Herpen, Wim J.G. Oyen, Winette T.A. van der Graaf & Otto C. Boerman. (2014) Theranostic applications of antibodies in oncology. Molecular Oncology 8:4, pages 799-812.
Crossref
Suzanne Hagan, Maria C M Orr & Brendan Doyle. (2013) Targeted therapies in colorectal cancer—an integrative view by PPPM. EPMA Journal 4:1.
Crossref
H Modjtahedi, S A Khelwatty, R S Kirk, A M Seddon, S Essapen, C A Del Vecchio, A J Wong & S Eccles. (2012) Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. British Journal of Cancer 106:5, pages 883-888.
Crossref
Lisa Rydén, Karin Jirström, Monica Haglund, Olle Stål & Mårten Fernö. (2010) Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Research and Treatment 120:2, pages 491-498.
Crossref
Robert Y. Osamura. (2009) Roles of pathologists in molecular targeted cancer therapy. Journal of Cellular and Molecular Medicine 13:11-12, pages 4286-4290.
Crossref
Helmout Modjtahedi & Sharadah Essapen. (2009) Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anti-Cancer Drugs 20:10, pages 851-855.
Crossref
Dina K. Patel. (2012) Clinical Use of Anti‐Epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28:11P2.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.